Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

SML0527

Sigma-Aldrich

Epalrestat

≥98% (HPLC)

Sinonimo/i:

(5Z)-5-[(2E)-2-Methyl-3-phenyl-2-propen-1-ylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C15H13NO3S2
Numero CAS:
82159-09-9
Peso molecolare:
319.40
Codice UNSPSC:
12352200
NACRES:
NA.77

Saggio

≥98% (HPLC)

Stato

powder

Condizioni di stoccaggio

protect from light

Colore

yellow to orange

Solubilità

DMSO: 5 mg/mL, clear (warmed)

Temperatura di conservazione

−20°C

Stringa SMILE

S1\C(=C/C(=C/c2ccccc2)/C)\C(=O)N(C1=S)CC(=O)O

InChI

1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-
CHNUOJQWGUIOLD-NFZZJPOKSA-N

Applicazioni

Epalrestat has been used as an aldose reductase inhibitor:
  • in the dahomey larvae diet fed forDrosophila
  • for non-irradiated and X-ray irradiated human aldose reductase
  • to test its protective effect in mice with bleomycin-induced pulmonary fibrosis

Azioni biochim/fisiol

Epalrestat inhibits Aldose Reductase (AR) involved in the rate limiting step in the conversion of glucose to sorbitol under hyperglycemic conditions. Aldose reductase has been the target of multiple clinical investigatons to treat diabetic neuropathy and retinopathy. Epalrestat is an approved drug in Japan and India, used for the treatment of diabetic neuropathy.
Epalrestat is an Aldose Reductase inhibitor.

Caratteristiche e vantaggi

This compound is featured on the Dopamine and Norepinephrine Metabolism page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Altre note

Light sensitve

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
037M4712V
033M4726V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 7

1 of 7

4-Bromophenylhydrazine hydrochloride 99%

Sigma-Aldrich

143219

4-Bromophenylhydrazine hydrochloride

2-Bromoacetophenone 98%

Sigma-Aldrich

115835

2-Bromoacetophenone

Vitexin analytical standard

Supelco

49513

Vitexin

DL-Glyceraldehyde ≥90% (GC)

Sigma-Aldrich

G5001

DL-Glyceraldehyde

DL-Sulforaphane ≥90% (HPLC), synthetic, liquid

Sigma-Aldrich

S4441

DL-Sulforaphane

Phenylhydrazine hydrochloride ≥99%

Sigma-Aldrich

114715

Phenylhydrazine hydrochloride

3,4-Dihydroxy-L-phenylalanine ≥98% (TLC)

Sigma-Aldrich

D9628

3,4-Dihydroxy-L-phenylalanine

Vincenzo Calderone et al.
The Journal of pharmacy and pharmacology, 62(1), 107-113 (2010-08-21)
Many observations report the cardioprotective effects of inhibitors of aldose reductase in different models of ischaemia-reperfusion injury in diabetic myocardium. In this paper, the inhibitory effects of the new pyrido[1,2-a]-pyrimidin-4-one derivative PPO, whose aldose reductase-inhibitory and antioxidant effects were shown
J W Steele et al.
Drugs & aging, 3(6), 532-555 (1993-11-01)
Epalrestat is a carboxylic acid derivative which inhibits aldose reductase, an enzyme of the sorbitol (polyol) pathway. Under hyperglycaemic conditions epalrestat reduces intracellular sorbitol accumulation, which has been implicated in the pathogenesis of late-onset complications of diabetes mellitus. Epalrestat 150
Ramakrishna Nirogi et al.
Journal of pharmaceutical and biomedical analysis, 74, 227-234 (2012-12-19)
A simple and rapid LC-MS/MS method was developed and validated for the quantification of epalrestat, an aldose reductase inhibitor for the treatment of diabetic neuropathy. Following protein precipitation epalrestat and IS were eluted with 10mM ammonium acetate and acetonitrile using
Mary Ann Ramirez et al.
Pharmacotherapy, 28(5), 646-655 (2008-05-02)
Diabetic neuropathy is one of the most common long-term complications in patients with diabetes mellitus, with a prevalence of 60-70% in the United States. Treatment options include antidepressants, anticonvulsants, tramadol, and capsaicin. These agents are modestly effective for symptomatic relief
Bruno Bulic et al.
Neuropharmacology, 59(4-5), 276-289 (2010-02-13)
Alzheimer disease is characterized by pathological aggregation of two proteins, tau and Abeta-amyloid, both of which are considered to be toxic to neurons. In this review we summarize recent advances on small molecule inhibitors of protein aggregation with emphasis on
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.